Compare Crispr Therapeutics AG (CRSP) vs Ecopetrol SA (EC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Ecopetrol SA — how do they compare? Crispr Therapeutics AG trades at $50.71 (market cap $4.97B), while Ecopetrol SA trades at $16.19 (market cap $29.46B). The key difference: Ecopetrol SA is far larger — about 5.9× Crispr Therapeutics AG's market cap, and Ecopetrol SA pays a 4.02% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | EC | |
|---|---|---|
Market Cap | $4.97B | $29.46B |
Sector | Health | Energy |
52-Week High | $76.78 | $16.58 |
52-Week Low | $44.34 | $8.29 |
Enterprise Value | $3.32B | $57.24B |
Dividend Yield | — | 4.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Ecopetrol (EC) trades at $15.88, up 1.93% with a bullish technical signal from moving averages. The stock shows mixed earnings performance with recent misses but maintains solid profitability with 8.76% net margin and 13.01% ROE. Recent positive developments include a collective bargaining agreement with workers and S&P credit rating affirmation. Valuation appears reasonable with P/E of 11.31 and P/S of 0.99, trading near analyst consensus target of $14.63.
EC presents a balanced opportunity with attractive valuation metrics and stable dividend yield, though facing revenue decline from $159.6B in 2022 to $119.7B in 2025. Key risks include ongoing revenue pressure, debt levels at 42.51% of assets, and oil price volatility. Analyst sentiment is cautious with 27% buy ratings versus 55% hold, suggesting limited near-term upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →
